Takeda Pharmaceutical Co Ltd
TAKHealthcare|Drug Manufacturers - Specialty & Generic|Japan
$16.56
-0.05 (-0.30%)
DCF (FCF)
$23.41
Financials
Financial Snapshot
Market Cap
$52.88B
Enterprise Value
$-26.26B
Revenue (TTM)
$29.73B
Net Income (TTM)
$-877.2M
Cash & Equivalents
—
Net Cash/Share
$-14.56
Free Cash Flow (TTM)
$4.20B
Operating CF (TTM)
$6.91B
Debt/Equity
0.66
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $3.33B | $3.54B | $6.53B | $6.07B | $9.23B | $7.38B | $4.14B | $3.16B | $2.72B | $4.01B | $4.01B | |
| Operating Cash Flow | $2.31B | $3.56B | $2.96B | $6.22B | $9.30B | $9.47B | $7.31B | $4.78B | $7.09B | $6.56B | $6.91B | |
| Free Cash Flow | $1.32B | $2.35B | $1.75B | $4.20B | $7.12B | $7.90B | $2.57B | $1.57B | $4.55B | $3.95B | $4.20B | |
| Capital Expenditure | $-992.1M | $-1.21B | $-1.21B | $-2.02B | $-2.18B | $-1.57B | $-4.74B | $-3.21B | $-2.55B | $-2.61B | $-2.71B | |
| Financing Cash Flow | $2.57B | $-3.08B | $26.51B | $-9.34B | $-10.01B | $-9.03B | $-5.31B | $-2.37B | $-5.04B | $-3.13B | $-3.29B |
R&D Spending
R&D (TTM)
$4.44B
R&D Intensity
14.9%
R&D Growth YoY
+4.3%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.34B | $16.70B | $18.87B | $30.57B | $29.42B | $30.10B | $30.13B | $28.46B | $30.74B | $28.39B | $29.73B | |
| R&D Expense | $2.77B | $3.07B | $3.31B | $4.57B | $4.19B | $4.44B | $4.74B | $4.87B | $4.90B | $4.26B | $4.44B | |
| R&D % of Revenue | 18.0% | 18.4% | 17.6% | 15.0% | 14.3% | 14.7% | 15.7% | 17.1% | 15.9% | 15.0% | 14.9% | |
| SG&A | $5.48B | $5.92B | $6.46B | $8.96B | $8.06B | $7.47B | $7.46B | $7.03B | $7.41B | $6.83B | $7.14B |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.34B | $16.70B | $18.87B | $30.57B | $29.42B | $30.10B | $30.13B | $28.46B | $30.74B | $28.39B | $29.73B | |
| Cost of Goods Sold | $4.95B | $4.68B | $5.86B | $10.12B | $9.15B | $9.33B | $9.31B | $9.52B | $10.60B | $9.90B | $10.36B | |
| Gross Profit | $10.39B | $12.02B | $13.01B | $20.45B | $20.27B | $20.76B | $20.82B | $18.94B | $20.14B | $18.49B | $19.36B | |
| R&D | $2.77B | $3.07B | $3.31B | $4.57B | $4.19B | $4.44B | $4.74B | $4.87B | $4.90B | $4.26B | $4.44B | |
| SG&A | $5.48B | $5.92B | $6.46B | $8.96B | $8.06B | $7.47B | $7.46B | $7.03B | $7.41B | $6.83B | $7.14B | |
| Operating Income | $868.7M | $1.76B | $1.73B | $2.66B | $3.84B | $4.60B | $4.40B | $2.07B | $3.13B | $2.93B | $3.09B | |
| Interest Expense | $-67.0M | $-94.6M | $-433.3M | $-1.38B | $-1.20B | $-1.03B | $-875.1M | $-797.9M | $-921.2M | $-933.5M | $-1.05B | |
| Pretax Income | $1.27B | $2.05B | $1.15B | $-564.3M | $3.37B | $2.55B | $2.81B | $352.4M | $1.17B | $-897.1M | $-775.9M | |
| Net Income | $1.02B | $1.76B | $1.22B | $410.9M | $3.46B | $1.94B | $2.37B | $961.6M | $724.1M | $-960.3M | $-877.2M | |
| EPS (Diluted) | 0.65 | 1.12 | 0.63 | 0.13 | 1.10 | 0.61 | 0.76 | 0.30 | 0.23 | -0.30 | -0.29 | |
| EBITDA | $2.85B | $3.86B | $3.81B | $6.24B | $9.72B | $8.50B | $8.65B | $6.01B | $7.20B | $4.58B | $5.18B | |
| Shares Out. (M) | 1571.78 | 1573.41 | 1933.79 | 3132.41 | 3147.07 | 3154.34 | 3139.74 | 3160.69 | 3210.65 | 3150.12 | 3158.61 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.83B | $2.78B | $6.32B | $5.92B | $8.89B | $7.17B | $3.99B | $3.06B | $2.58B | $3.75B | $3.75B | |
| Marketable Securities | $502.0M | $760.5M | $209.4M | $147.0M | $336.7M | $213.4M | $150.9M | $100.7M | $137.4M | $264.0M | $264.0M | |
| Total Current Assets | $11.16B | $10.17B | $26.93B | $22.94B | $24.96B | $21.87B | $17.94B | $17.08B | $16.91B | $19.48B | $19.48B | |
| Total Assets | $38.50B | $38.72B | $124.10B | $119.08B | $118.79B | $111.13B | $104.42B | $100.85B | $95.59B | $97.75B | $97.75B | |
| Total Current Liabilities | $12.10B | $6.95B | $22.97B | $20.21B | $16.31B | $18.10B | $18.57B | $15.44B | $16.82B | $17.85B | $17.85B | |
| Long-Term Debt | $5.31B | $9.29B | $42.88B | $41.86B | $42.44B | $34.93B | $30.25B | $29.88B | $26.61B | $27.54B | $27.54B | |
| Total Liabilities | $21.24B | $19.70B | $77.44B | $75.17B | $71.16B | $63.20B | $56.88B | $52.30B | $49.06B | $50.92B | $50.92B | |
| Stockholders' Equity | $16.78B | $18.84B | $46.62B | $43.87B | $47.59B | $47.93B | $47.54B | $48.55B | $46.53B | $46.82B | $46.82B | |
| Retained Earnings | $13.39B | $14.69B | $14.35B | $12.72B | $13.89B | $12.48B | $11.53B | $9.29B | $7.97B | $4.49B | $4.49B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.31B | $3.56B | $2.96B | $6.22B | $9.30B | $9.47B | $7.31B | $4.78B | $7.09B | $6.56B | $6.91B | |
| Capital Expenditure | $-992.1M | $-1.21B | $-1.21B | $-2.02B | $-2.18B | $-1.57B | $-4.74B | $-3.21B | $-2.55B | $-2.61B | $-2.71B | |
| Free Cash Flow | $1.32B | $2.35B | $1.75B | $4.20B | $7.12B | $7.90B | $2.57B | $1.57B | $4.55B | $3.95B | $4.20B | |
| Investing Cash Flow | $-5.81B | $-880.2M | $-25.51B | $2.71B | $3.62B | $-1.67B | $-4.54B | $-3.10B | $-2.46B | $-2.33B | $-2.39B | |
| Financing Cash Flow | $2.57B | $-3.08B | $26.51B | $-9.34B | $-10.01B | $-9.03B | $-5.31B | $-2.37B | $-5.04B | $-3.13B | $-3.29B | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $-204.7M | $-176.9M | $-10.5M | $-34.7M | $-19.7M | $-653.8M | $-201.5M | $-15.5M | $-347.9M | $-325.2M | $-357.2M | |
| Issuance of Debt | $5.91B | $3.71B | $28.46B | $4.61B | $10.85B | $2.10B | $860.4M | $2.52B | $7.06B | $3.69B | $3.96B | |
| Payments of Debt | $-1.73B | $-5.15B | $-15.7M | $-10.05B | $-16.93B | $-7.17B | $-2.99B | $-2.51B | $-9.17B | $-3.69B | $-3.94B | |
| Stock Based Comp. | $136.3M | $175.5M | $180.7M | $270.5M | $346.5M | $365.8M | $453.9M | $473.0M | $488.9M | $458.6M | $479.5M | |
| Net Change in Cash | $-975.7M | $-436.4M | $3.67B | $-604.7M | $3.02B | $-982.7M | $-2.37B | $-505.5M | $-487.7M | $1.32B | $1.45B |
Dilution Tracker
Shares Outstanding
3159M
5-Year Share Growth
+0.1%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1571.78 | 1573.41 | 1933.79 | 3132.41 | 3147.07 | 3154.34 | 3139.74 | 3160.69 | 3210.65 | 3150.12 | 3158.61 | |
| YoY Change % | — | 0.1% | 22.9% | 62.0% | 0.5% | 0.2% | -0.5% | 0.7% | 1.6% | -1.9% | 0.3% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $-204.7M | $-176.9M | $-10.5M | $-34.7M | $-19.7M | $-653.8M | $-201.5M | $-15.5M | $-347.9M | $-325.2M | $-357.2M | |
| Stock Based Comp. | $136.3M | $175.5M | $180.7M | $270.5M | $346.5M | $365.8M | $453.9M | $473.0M | $488.9M | $458.6M | $479.5M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 67.7% | 72.0% | 68.9% | 66.9% | 68.9% | 69.0% | 69.1% | 66.5% | 65.5% | 65.1% | 65.1% | |
| Operating Margin % | 5.7% | 10.6% | 9.2% | 8.7% | 13.1% | 15.3% | 14.6% | 7.3% | 10.2% | 10.3% | 10.4% | |
| Net Margin % | 6.6% | 10.6% | 6.4% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% | -3.4% | -3.0% | |
| EBITDA Margin % | 18.6% | 23.1% | 20.2% | 20.4% | 33.0% | 28.2% | 28.7% | 21.1% | 23.4% | 16.1% | 17.4% | |
| FCF Margin % | 8.6% | 14.1% | 9.3% | 13.7% | 24.2% | 26.3% | 8.5% | 5.5% | 14.8% | 13.9% | 14.1% | |
| ROE % | 6.0% | 9.9% | 3.7% | 0.9% | 7.6% | 4.1% | 5.0% | 2.0% | 1.5% | -2.1% | -1.8% | |
| ROA % | 2.8% | 4.6% | 1.5% | 0.3% | 2.9% | 1.7% | 2.2% | 0.9% | 0.7% | -1.0% | -0.9% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 30.77 / 537.91
Industry Med.20.77
P/S1.90
Historical1.38 / 1.76 / 2.93
Industry Med.2.30
P/B1.14
Historical0.82 / 1.13 / 2.46
Industry Med.1.91
EV/EBITDA17.14
Historical6.93 / 10.48 / 28.09
Industry Med.12.99
EV/Revenue2.84
Historical2.03 / 2.70 / 5.73
Industry Med.2.45
P/FCF13.68
Historical5.47 / 13.29 / 54.77
Industry Med.20.81
Intrinsic Value Models
DCF (FCF Based)
$23.41
Median P/S Value
$15.43
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | 35.75 | 21.82 | 32.33 | 117.10 | 16.68 | 23.98 | 21.54 | 45.89 | 65.64 | At Loss | At Loss | |
| PS Ratio | 2.37 | 2.30 | 2.08 | 1.57 | 1.96 | 1.55 | 1.70 | 1.55 | 1.55 | 1.98 | 1.90 | |
| PB Ratio | 2.20 | 2.03 | 1.36 | 1.08 | 1.20 | 0.93 | 1.08 | 0.90 | 1.01 | 1.25 | 1.14 | |
| EV/EBITDA | 15.22 | 11.43 | 28.48 | 14.28 | 9.34 | 8.85 | 9.16 | 12.15 | 10.30 | 18.15 | 17.14 | |
| EV/Revenue | 2.83 | 2.64 | 5.75 | 2.92 | 3.09 | 2.50 | 2.63 | 2.56 | 2.41 | 2.93 | 2.84 |
Analyst Estimates & Quality
Altman Z-Score
1.01
Distress
Piotroski F-Score
5
Moderate
Beneish M-Score
-2.51
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $28,828M | $29,754M | $30,563M |
| Net Income | $4,826M | $4,977M | $5,448M |
| EPS | 0.69 | 0.46 | 0.00 |
| Book Value per Share | 28.47 | 28.49 | 29.11 |
| Operating Cash Flow per Share | 577.39 | 559.57 | 0.00 |
| Operating CF | $1,823,750.35M | $1,767,450.10M | $0.00M |
Dividends
Dividend/Share (TTM)
$0.64
Dividend Yield
3.81%
Yield 10Y Median
4.39%
Frequency
Semi-annually
Recent Payments
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-31 | 2026-07-06 | $0.308273 | Cash Div. |
| 2025-09-30 | 2025-12-11 | $0.322144 | Cash Div. |
| 2025-03-31 | 2025-07-07 | $0.33901 | Cash Div. |
| 2024-09-30 | 2024-12-12 | $0.326079 | Cash Div. |
| 2024-03-27 | 2024-07-08 | $0.292214 | Cash Div. |
| 2023-09-28 | 2023-12-11 | $0.319068 | Cash Div. |
| 2023-03-30 | 2023-07-10 | $0.30996 | Cash Div. |
| 2022-09-29 | 2022-12-12 | $0.329553 | Cash Div. |
| 2022-03-30 | 2022-07-11 | $0.330062 | Cash Div. |
| 2021-09-29 | 2021-12-13 | $0.396898 | Cash Div. |
| 2021-03-30 | 2021-07-12 | $0.406627 | Cash Div. |
| 2020-09-29 | 2020-12-11 | $0.430533 | Cash Div. |
| 2020-03-30 | 2020-07-06 | $0.419053 | Cash Div. |
| 2019-09-27 | 2019-12-12 | $0.411118 | Cash Div. |
| 2019-03-28 | 2019-07-10 | $0.417168 | Cash Div. |
| 2018-09-27 | 2018-12-13 | $0.395501 | Cash Div. |
| 2018-03-28 | 2018-07-09 | $0.40643 | Cash Div. |
| 2017-09-28 | 2017-12-11 | $0.39946 | Cash Div. |
| 2017-03-29 | 2017-07-10 | $0.39892 | Cash Div. |
| 2016-09-28 | 2016-12-12 | $0.392415 | Cash Div. |
Revenue Segments
By Business
| Segment | 2026 |
|---|---|
| Gastroenterology (GI) | $1407.46B |
| Neuroscience | $414.34B |
| Oncology | $580.13B |
| Other | $223.96B |
| Plasma Derived Therapies (PDT) | $1057.52B |
| Rare Diseases | $762.70B |
| Vaccines | $59.61B |
By Geography
| Segment | 2026 |
|---|---|
| United States (US) | $2164.82B |
| Asia (excluding Japan & China) | $98.67B |
| China | $195.14B |
| Europe and Canada | $1146.24B |
| Japan | $433.11B |
| Latin America | $254.13B |
| Other | $133.89B |
| Russia/Commonwealth of Independent States (CIS) | $79.72B |